npj Vaccines
(Feb 2024)
A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression
Huajun Zhao,
Xianyu Shao,
Yating Yu,
Lulu Huang,
Narh Philip Amor,
Kun Guo,
Changzhen Weng,
Weijun Zhao,
Ailu Yang,
Jiesen Hu,
Hongbao Yang,
Zhenguang Liu,
Qiuju Han,
Leilei Shi,
Shiyu Sun,
Jian Zhang,
Ang Lin,
Yong Yang
Affiliations
Huajun Zhao
Institute of Immunopharmaceutical Sciences, Key Laboratory of Chemical Biology, School of Pharmaceutical Sciences, Shandong University
Xianyu Shao
Vaccine Center, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University
Yating Yu
Institute of Immunopharmaceutical Sciences, Key Laboratory of Chemical Biology, School of Pharmaceutical Sciences, Shandong University
Lulu Huang
Vaccine Center, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University
Narh Philip Amor
Vaccine Center, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University
Kun Guo
Vaccine Center, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University
Changzhen Weng
Vaccine Center, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University
Weijun Zhao
Vaccine Center, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University
Ailu Yang
Institute of Immunopharmaceutical Sciences, Key Laboratory of Chemical Biology, School of Pharmaceutical Sciences, Shandong University
Jiesen Hu
Firestone Biotechnologies
Hongbao Yang
Center for New Drug Safety Evaluation and Research, China Pharmaceutical University
Zhenguang Liu
College of Veterinary Medicine, Nanjing Agricultural University
Qiuju Han
Institute of Immunopharmaceutical Sciences, Key Laboratory of Chemical Biology, School of Pharmaceutical Sciences, Shandong University
Leilei Shi
Precision Research Center for Refractory Diseases in Shanghai General Hospital, Shanghai Jiao Tong University
Shiyu Sun
Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences
Jian Zhang
Institute of Immunopharmaceutical Sciences, Key Laboratory of Chemical Biology, School of Pharmaceutical Sciences, Shandong University
Ang Lin
Vaccine Center, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University
Yong Yang
Vaccine Center, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University
DOI
https://doi.org/10.1038/s41541-024-00813-3
Journal volume & issue
Vol. 9,
no. 1
Abstract
Read online
Abstract Here we report on the development and comprehensive evaluations of an mRNA vaccine for chronic hepatitis B (CHB) treatment. In two different HBV carrier mouse models generated by viral vector-mediated HBV transfection (pAAV-HBV1.2 and rAAV8-HBV1.3), this vaccine demonstrates sufficient and persistent virological suppression, and robust immunogenicity in terms of induction of strong innate immune activation, high-level virus-specific antibodies, memory B cells and T cells. mRNA platform therefore holds prospects for therapeutic vaccine development to combat CHB.
Published in npj Vaccines
ISSN
2059-0105 (Online)
Publisher
Nature Portfolio
Country of publisher
United Kingdom
LCC subjects
Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website
https://www.nature.com/npjvaccines/
About the journal
WeChat QR code
Close
